Detection method for PR genes of circulating tumor cells in peripheral blood of later-period breast cancer patient

Abstract

The invention discloses a detection method for PR genes of circulating tumor cells in peripheral blood of a later-period breast cancer patient. The detection method comprises the steps that the CTCs in the peripheral blood of the later-period breast cancer patient are separated and acquired through a film filtering device; the circulating tumor cells in the peripheral blood of the later-period breast cancer patient are identified through a cellular immunity fluorescent technique; thin sections are made through a cell wax block technique; the expression condition of the PR of the circulating tumor cells in the peripheral blood of the later-period breast cancer patient is detected through an immunologic tissue chemical technique. According to the detection method, the enrichment CTCs are separated with the help of an ISET technique, the CTCs are identified by depending on the cellular immunity fluorescent technique, and therefore the difficulties existing in CTC identification only through the ISET technique and the false negativity existing in CTC identification only through an immunological detection technique are overcome. The technology has the advantages that the requirement on equipment is not high, the method is easy to master, and real-time monitoring can be achieved. Through the technical method, the expression condition of the PR of the later-period breast cancer patient can be detected without needing to sample the breast cancer tissue. The technology belongs to a minimally invasive technology or even a non-invasive technology and can achieve real-time detection.

Description

Technical field [0001] The invention relates to a new method for detecting PR genes, in particular to a method for detecting PR genes of patients with advanced breast cancer through peripheral blood. Background technique [0002] At present, the progesterone receptor (PR), which is a prognostic factor, is a product of ER, which can cause and enhance the response of estrogen to ER, and play a promoting and synergistic effect. It has become the most important factor in formulating endocrine treatment programs for breast cancer patients. An important indicator is that only when ER is positive, the effective rate of endocrine therapy is 50%-60%. If both ER and PR are positive, the effective rate can be as high as 70%-80%, while the effective rate of negative patients is 10%. Existing breast cancer PR detection requires surgery or needle biopsy to obtain tumor tissue samples of primary tumors or metastases. However, not every patient can obtain tumor tissue samples, and continuous tre...

AI Technical Summary

Problems solved by technology

[0005] In order to overcome the shortcomings of the traditional circulating tumor cell detection technology and the unsuitable tissue sample collection for patients with advanced breast cancer-thereby inability to evaluate the PR status of patients, the present invention provides a detection method for PR genes in peripheral blood circulating tumor cells of patients with advanced breast cancer: using Separation and acquisition of CTCs in peripheral blood of patients with advanced breast cancer by membrane filtration device; identification of circulating tumor cells in peripheral blood of patients with advanced breast cancer by cell immunofluorescence technology; use of cell wax block technology to make thin-layer sections; and detection of advanced breast cancer by immunohistochemistry PR expression of circulating tumor cells in peripheral blood of patients

Images